Flucinar, gel 0.025% 15 g

Flucinar is a synthetic GKS for external use. It has anti-inflammatory, antipruritic, anti-allergic, anti-exudative effects.

The mechanism of anti-inflammatory action is not fully understood. Fluocinolone acetonide inhibits the synthesis of prostaglandins and leukotrienes by inhibition of phospholipase A2 activity and reduces the release of arachidonic acid from phospholipids of the cell membrane. It prevents local allergic reactions in the skin. Antiexudative effect is caused by the vasoconstrictor action.

Easy penetration into the skin through the stratum corneum. It is not biotransformed in the skin and it accumulates in the stratum corneum. Fluociolone acetonide is detectable in the skin even after 15 days after topical application.

When used topically, fluocinolone acetonide may be slightly absorbed into the systemic bloodstream and cause general effects. The absorbed part is biotransformed mainly in the liver and is excreted from the body as compounds with glucuronic acid and in small amounts in unbound form. It is excreted mainly with urine and slightly with bile.

Absorption of fluocinolone acetonide is more pronounced when it is applied to the face and affected areas of the skin, as well as when using occlusive dressings. In addition, absorption of the drug increases when it is used frequently and when applied to large areas of skin. Absorption of the drug in children is more pronounced than in adults.

Indications

Psoriasis of the scalp;
seborrheic dermatitis, especially of scalp areas;
lichen planus, accompanied by severe itching;
pruritus.

Flucinar in the form of a gel is indicated for the treatment of skin covered with hair, as well as for patients who do not tolerate the drug in the form of an ointment due to the components of the ointment base.

Pharmacological effect

Flucinar is a synthetic GCS for external use. It has anti-inflammatory, antipruritic, anti-allergic, anti-exudative effects.

The mechanism of anti-inflammatory action is not fully understood. Fluocinolone acetonide inhibits the synthesis of prostaglandins and leukotrienes by inhibiting the activity of phospholipase A2 and reduces the release of arachidonic acid from cell membrane phospholipids. Prevents the occurrence of local allergic reactions in the skin. The antiexudative effect is due to the vasoconstrictor effect.

Easily penetrates the skin through the stratum corneum. It does not undergo biotransformation in the skin and accumulates in the stratum corneum. Fluociolone acetonide is detectable in the skin even 15 days after its topical application.

When fluocinolone is used externally, acetonide can be absorbed to a small extent into the systemic circulation and cause general symptoms. The absorbed part is biotransformed mainly in the liver and excreted from the body in the form of compounds with glucuronic acid and in a small amount in an unbound form. Excreted mainly in urine and slightly in bile.

Absorption of fluocinolone acetonide is more pronounced when applied to the face and affected areas of the skin, as well as when using occlusive dressings. In addition, absorption of the drug increases with frequent use and when applied to large areas of the skin. Absorption of the drug in children is more pronounced than in adults.

Active ingredient

Fluocinolone acetonide

Composition

1 g of gel contains:

Active substance:

fluocinolone acetonide 0.25 mg;

Excipients:

propylene glycol;

ethanol;

disodium salt of ethylenediaminetetraacetic acid (trilon B);

citric acid;

methylhydroxybenzoate;

propylhydroxybenzoate;

carbopol 940;

triethanolamine;

purified water.

Contraindications

Hypersensitivity;
acne;
bacterial (including tuberculosis), fungal, viral and tumor diseases of the skin.

Side Effects

Atrophy of the skin and subcutaneous fat, lupus-like syndrome with a mild course, the appearance or exacerbation of symptoms of lichen planus, epithelialization disorders, delayed healing of wounds and ulcerative lesions, petechiae, steroid purpura, stretch marks, hirsutism, baldness in women, maculopapular skin rash.

Overdose

Symptoms: if the dosage regimen is not followed (long-term use of the drug over large areas of the skin), systemic side effects of the drug may develop, such as increased blood pressure, edema, and immunosuppressive effects.

Treatment: drug withdrawal.

Storage conditions

At a temperature not exceeding 25 °C. Do not freeze.

Shelf life

3 years

Manufacturer

Pharmaceutical plant Elfa A.O., Poland